A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas

Trial Profile

A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs FF 10502 (Primary)
  • Indications Lymphoma; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors FujiFilm Pharmaceuticals USA
  • Most Recent Events

    • 05 Apr 2017 Results (n=22) of phase I, presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 29 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top